2019
DOI: 10.1016/j.exer.2019.107821
|View full text |Cite
|
Sign up to set email alerts
|

HSP90 as a novel therapeutic target for posterior capsule opacification

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(18 citation statements)
references
References 34 publications
0
18
0
Order By: Relevance
“…The results of the present study showed that HSP90 was significantly expressed in the testicular tissue of diabetic rats compared with control group rats ( p < 0.001), although HSP90 is potentially important in offering cytoprotection at physiological limits [ 24 ]. But in the case where its upregulation is increased, it is expected to develop negative impacts through inhibition of production of other HSPs that lead to the cytoprotection [ 25 28 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The results of the present study showed that HSP90 was significantly expressed in the testicular tissue of diabetic rats compared with control group rats ( p < 0.001), although HSP90 is potentially important in offering cytoprotection at physiological limits [ 24 ]. But in the case where its upregulation is increased, it is expected to develop negative impacts through inhibition of production of other HSPs that lead to the cytoprotection [ 25 28 ].…”
Section: Discussionmentioning
confidence: 99%
“…Heat shock protein (HSP) 90 exists in cells as a chaperone that acts in controlling cellular changes such as protein refolding, removing denatured proteins through the process of the proteasome [ 24 ]. HSP90 participates in making what is called the machine of chaperone [ 24 ]. Various types of stress can induce the production of HSP90 including cancer and diabetes [ 24 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, its role in PCO is not known. Li et al [51] investigated the potential therapeutic use of HSP90 in PCO using an LEC line and an ex vivo rat lens capsule. Protein expression in response to application of tanespimycin (17-AAG), an HSP90 inhibitor, was assessed by immunoblotting and real-time polymerase chain reaction (RT-PCR) and apoptosis by the TdT-mediated dUTP nick-end labeling method.…”
Section: In Vitro Research Involving Photodynamic Therapymentioning
confidence: 99%
“…However, its role in PCO is not known. Li et al (53) investigated the potential therapeutic use of HSP90 in PCO using an LEC line and an ex vivo rat lens capsule. Protein expression in response to application of tanespimycin (17-AAG), an HSP90 inhibitor, was assessed by immunoblotting and real-time polymerase chain reaction (RT-PCR) and apoptosis by the TdT-mediated dUTP nick-end labeling (TUNEL) method.…”
Section: Ex Vivo Tests With Heat Shock Protein 90mentioning
confidence: 99%